UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q2 2022 | 2022-08-11 | Future report Set alerts | |
| Q1 2022 | 2022-05-05 | -0.21 | -0.21 |
| Q4 2021 | 2022-02-28 | -0.31 | -0.31 |
| Q3 2021 | 2021-11-12 | -0.42 | -0.42 |
| Q2 2021 | 2021-08-13 | -0.45 | -0.45 |
| Q1 2021 | 2021-05-06 | -0.34 | -0.34 |
| Q4 2020 | 2021-03-08 | -0.32 | -0.32 |
| Q3 2020 | 2020-11-05 | -0.20 | -0.20 |
| Q2 2020 | 2020-08-06 | -0.28 | -0.28 |
| Q1 2020 | 2020-05-07 | -0.25 | -0.25 |
| 2016-06-23 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-06-23 | Reiterated Rating | Wedbush | Outperform | $24.00 |
| 2016-06-22 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-05-10 | Reiterated Rating | Leerink Swann | Buy | $17.00 |
| 2016-03-31 | Initiated Coverage | Ladenburg Thalmann | Buy | $21.00 |
| 2016-03-16 | Reiterated Rating | Leerink Swann | Outperform | $20.00 |
| 2016-03-09 | Lower Price Target | JPMorgan Chase & Co. | Market Outperform | $26.00 to $21.00 |
| 2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $26.00 to $21.00 |
| 2016-03-08 | Initiated Coverage | Cantor Fitzgerald | Buy | $19.00 |
| 2016-03-07 | Lower Price Target | Leerink Swann | Outperform | $30.00 to $20.00 |
| 2016-03-04 | Reiterated Rating | Wedbush | Outperform | $24.00 |
| 2016-03-03 | Initiated Coverage | Citigroup Inc. | Buy | $15.00 |
| 2016-01-05 | Reiterated Rating | Wedbush | Outperform | $24.00 |
| 2015-12-18 | Initiated Coverage | BTIG Research | Buy | $33.00 |
| 2015-09-22 | Initiated Coverage | BTIG Research | Buy | $33.00 |
| 2015-09-03 | Reiterated Rating | Wedbush | Outperform | $24.00 |
| 2015-08-19 | Reiterated Rating | Wedbush | Buy | |
| 2015-08-18 | Boost Price Target | Wedbush | Outperform | $19.00 to $24.00 |
| 2015-06-04 | Boost Price Target | Leerink Swann | Outperform | $22.00 to $25.00 |
| 2015-05-07 | Lower Price Target | Citigroup Inc. | Buy | $20.00 to $14.00 |
| 2015-05-06 | Lower Price Target | Leerink Swann | Outperform | $32.00 to $22.00 |
| 2015-05-06 | Lower Price Target | JMP Securities | Market Outperform | $32.00 to $24.00 |
| 2015-02-03 | Lower Price Target | Leerink Swann | Outperform | $36.00 to $32.00 |
| 2015-02-02 | Reiterated Rating | Wedbush | Outperform | $31.00 |
| 2014-07-14 | Initiated Coverage | Wedbush | Outperform | $31.00 |
| 2014-07-14 | Initiated Coverage | Leerink Swann | Outperform | $32.00 |
| 2014-07-14 | Initiated Coverage | JMP Securities | Outperform | $26.00 |
| 2014-07-14 | Initiated Coverage | Citigroup Inc. | Buy | $27.00 |
| 2016-06-23 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-06-23 | Reiterated Rating | Wedbush | Outperform | $24.00 |
| 2016-06-22 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-05-10 | Reiterated Rating | Leerink Swann | Buy | $17.00 |
| 2016-03-31 | Initiated Coverage | Ladenburg Thalmann | Buy | $21.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ARDX 0 funds of 2220 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| KERINS PATRICK J | 47.23% (8752543) | ARDX / CLVS / CRCM / CVT / ECHO / ECOM / EPZM / HIVE / HPTX / LOXO / MM / ROKA / SNSS / SURF / SYBX / TSRO / |
| BARRETT M JAMES | 47.23% (8752543) | ADNC / ARDX / CLVS / CRCM / CVT / DATA / ECHO / EPZM / FOLD / GLYC / HIVE / HPTX / INWK / LOXO / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WIFI / XOOM / ZSAN / |
| New Enterprise Associates 12, Limited Partnership | 47.23% (8752543) | ARDX / ECHO / ECOM / HPTX / OPWR / TNTR / TRVN / ZSAN / |
| DRANT RYAN D | 40.41% (7488893) | ADNC / ARDX / CLVS / CRCM / CVT / DATA / ECHO / EPZM / HIVE / HPTX / INWK / LOXO / ROKA / SNSS / TSRO / XOOM / |
| NEA 15 GP, LLC | 14.38% (2665519) | ARDX / |
| MAKOWER JOSHUA | 14.38% (2665519) | ABIO / AKAO / ARDX / AVEO / ONTY / |
| Sonsini Peter W. | 14.38% (2665519) | ABIO / AKAO / ARDX / AVEO / LOXO / ONTY / SURF / SYBX / |
| Florence Anthony A. Jr. | 14.38% (2665519) | ABIO / AKAO / ARDX / AVEO / CVT / LOXO / ONTY / SURF / SYBX / |
| Viswanathan Ravi | 14.38% (2665519) | ABIO / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / EPZM / HIVE / LOXO / ONTY / ROKA / SURF / SYBX / TSRO / |
| KOLLURI KRISHNA KITTU | 14.38% (2665519) | ADNC / AKAO / ARDX / CLVS / CRCM / CVT / DATA / ECHO / EPZM / HIVE / HPTX / INWK / LOXO / ROKA / SNSS / SUPN / TSRO / XOOM / |
| BARRIS PETER J | 14.38% (2665519) | ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / GLYC / GRPN / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WIFI / XOOM / ZHNE / |
| Weller Harry R | 14.38% (2665519) | ARDX / CLVS / CRCM / CVT / EPZM / HIVE / LOXO / OPWR / ROKA / TSRO / |
| SANDELL SCOTT D | 14.38% (2665519) | ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / FIO / GLYC / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WDAY / WIFI / XOOM / |
| Sakoda Jon | 14.38% (2665519) | ABIO / AKAO / ARDX / AVEO / ONTY / OPWR / |
| SCHULTZ PETER G | 4.91% (910339) | ARDX / |
| Seeto Reginald Chief Operating Officer | 0.85% (158133) | ARDX / |
| RAAB MICHAEL President & CEO | 0.53% (99038) | ARDX / FOLD / |
| Jacobs Jeffrey W VP, Chemistry | 0.37% (68450) | ARDX / |
| Rosenbaum David P. SVP, Drug Development | 0.36% (66641) | ARDX / |
| CMEA Ventures VII LP | 0.34% (63490) | ARDX / ASPX / NEOS / |
| Korner Paul EVP, Chief Medical Officer | 0.29% (54623) | ARDX / |
| Kaufmann Mark Chief Financial Officer | 0.26% (48588) | ARDX / |
| GRAMMER ELIZABETH A VP, General Counsel | 0.21% (38894) | ARDX / |
| MOTT DAVID M | 0.18% (33877) | ABIO / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / EPZM / HIVE / LOXO / ONTY / ROKA / SURF / SYBX / TSRO / |
| Rodgers Richard J | 0.15% (26993) | ARDX / RNN / TSRO / |
| JUE GEORGE VP, Operations & Facilities | 0.13% (24134) | ARDX / |
| Bertrand William C JR | 0.12% (21481) | ARDX / INFI / SLXP / |
| Caldwell Jeremy S EVP, Chief Scientific Officer | 0.10% (17985) | ARDX / |
| RINGOLD GORDON | 0.08% (15000) | ALXA / ARDX / |
| Arasaratnam Narani VP, Corporate Controller | 0.01% (1232) | ARDX / |
UM